REGENXBIO Inc. (NASDAQ:RGNX) insider Kenneth T. Mills sold 10,000 shares of the business’s stock in a transaction on Friday, October 20th. The shares were sold at an average price of $32.62, for a total transaction of $326,200.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

REGENXBIO Inc. (RGNX) traded down 1.93% during mid-day trading on Tuesday, reaching $30.50. The company’s stock had a trading volume of 333,618 shares. The firm’s 50 day moving average price is $31.01 and its 200 day moving average price is $31.01. The stock’s market cap is $942.27 million. REGENXBIO Inc. has a 12-month low of $15.40 and a 12-month high of $36.10.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.34. The company had revenue of $6.56 million for the quarter. REGENXBIO had a negative return on equity of 38.74% and a negative net margin of 839.87%. On average, equities analysts predict that REGENXBIO Inc. will post ($2.93) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/24/regenxbio-inc-rgnx-insider-sells-326200-00-in-stock.html.

A number of analysts have recently commented on RGNX shares. Raymond James Financial, Inc. began coverage on shares of REGENXBIO in a report on Thursday, October 12th. They set an “outperform” rating and a $39.00 target price on the stock. Zacks Investment Research raised REGENXBIO from a “hold” rating to a “strong-buy” rating and set a $38.00 target price for the company in a research report on Wednesday, October 18th. Bank of America Corporation reissued a “buy” rating and issued a $38.00 target price (up previously from $33.00) on shares of REGENXBIO in a research report on Monday, October 9th. Chardan Capital reissued a “buy” rating and issued a $75.00 target price (up previously from $55.00) on shares of REGENXBIO in a research report on Tuesday, September 5th. Finally, Evercore ISI assumed coverage on REGENXBIO in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 target price for the company. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $40.00.

Hedge funds have recently bought and sold shares of the stock. Redmile Group LLC grew its stake in REGENXBIO by 35.4% during the 2nd quarter. Redmile Group LLC now owns 1,718,671 shares of the biotechnology company’s stock worth $33,944,000 after purchasing an additional 449,540 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of REGENXBIO by 4.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,226,835 shares of the biotechnology company’s stock worth $24,230,000 after acquiring an additional 51,041 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of REGENXBIO by 10.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,082,461 shares of the biotechnology company’s stock worth $21,379,000 after acquiring an additional 100,944 shares in the last quarter. Citadel Advisors LLC boosted its position in shares of REGENXBIO by 65.4% during the 2nd quarter. Citadel Advisors LLC now owns 926,176 shares of the biotechnology company’s stock worth $18,292,000 after acquiring an additional 366,289 shares in the last quarter. Finally, State Street Corp boosted its position in shares of REGENXBIO by 178.1% during the 2nd quarter. State Street Corp now owns 880,844 shares of the biotechnology company’s stock worth $17,399,000 after acquiring an additional 564,129 shares in the last quarter. Hedge funds and other institutional investors own 73.44% of the company’s stock.

About REGENXBIO

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Insider Buying and Selling by Quarter for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.